MYGN Financial Facts

Operating income: 36.2M
Research and development expense: 18.71M
See Full Income Statement

Accumulated deficit: -77M
Cash and cash equivalents: -120.62M
See Full Balance Sheet

Myriad Genetics Inc. (MYGN) Earnings

  |   Expand Research on MYGN
Next EPS Date 11/4/15 *Est. EPS Growth Rate -14.6% *Last Qtr.
Average EPS % Beat Rate -1.9% Revenue Growth Rate +0.6% *Last Qtr.
Average % Move 1-Wk after EPS -3.4% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/4/14 Q115 $0.25$0.32 -$0.07$168.8M$175M Details
8/11/15 Q415 $0.41$0.42 -$0.01$189.9M$187.77M Details
1/27/11 Q211 $0.26$0.26 $0.00$100.4M$98.84M Details
8/14/12 Q212 $0.34$0.34 $0.00$133M$131.85M = Details
8/9/11 Q411 $0.30$0.29 +$0.01$107.4M$104.43M = Details
11/1/11 Q112 $0.29$0.28 +$0.01$110.5M$106.49M = Details
11/2/10 Q111 $0.24$0.23 +$0.01N/AN/A Details
5/5/15 Q315 $0.40$0.39 +$0.01$180M$183.3M Details